10 - year experience in the application of biological therapy to patients with juvenile idiopathic arthritis

10 - летний опыт применения биологической терапии пациентам с ювенильным идиопатическим артритом
Zaure Mukusheva 1, Maikesh Asylbekova 1, Zhanara Albekova 1, Leyla Sadibekova 1
More Detail
1 Department of rheumatology of the Corporate Fund «University Medical Center» National Research Center for Maternal and Child Health, Astana, Kazakhstan
J CLIN MED KAZ, Volume 3, Issue 45 special issue, pp. 159-162. https://doi.org/10.23950/1812-2892-JCMK-00502
OPEN ACCESS 3207 Views 2564 Downloads
Download Full Text (PDF)

ABSTRACT

The article presents the experience of using biological agents for the treatment of children with juvenile idiopathic arthritis in the department of rheumatology of the Corporate Fund “University Medical Center” of the National Research Center for Maternal and Child Health.
Keywords: children, juvenile idiopathic arthritis, biological preparations, anti –TNFdrugs, anti-interleukin-6 drugs

CITATION

Mukusheva Z, Asylbekova M, Albekova Z, Sadibekova L. 10 - year experience in the application of biological therapy to patients with juvenile idiopathic arthritis. Journal of Clinical Medicine of Kazakhstan. 2017;3(45 special issue):159-62. https://doi.org/10.23950/1812-2892-JCMK-00502

REFERENCES

  • Petty R. E., Southwood T. R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. JRheumatol 2004; 31:390–2.
  • Godovajaforma №12 "Otchetochislezabolevanij, zaregistrirovannyhubol'nyh, prozhivajushhihvrajoneobsluzhivanijamedicin skojorganizaciiikontingentahbol'nyh, sostojashhihpoddispansernymnabljudeniem, dannyeMZRK 2016. (Annual report No. 12 "Report on the number of diseases registered in patients living in the service area of the medical organization and the contingent of patients under dispensary supervision, data from the Ministry of Health of the Republic of Kazakhstan 2016) [in Russian].
  • Andersson Gare B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. ClinExpRheumatol. 1999; 17:367–74.
  • Beukelman T., Patkar N. M., Saag K. G., et al. 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care & Research. 2011; 63:465–482.
  • Selvaag A. M., Flato B., Dale K., Lien G., Vinje O., Smerdel-Ramoya A., et al. Radiographic and clinical outcome in early juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3-year prospective study. J Rheumatol. 2006; 33:1382–91.
  • Packham J. C., Hall M. A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford).2002; 41:1428–35.
  • Raveli A., Martini A. Juvenile idiopatic arthritis. Lancet. 2007; 369(9563):767–778.
  • Lovell D. J., Reiff A., Ilowite N. T., Wallace C. A., Chon Y., Lin S. L., et al, for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58:1496–504.
  • Lovell D. J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359:810–20.
  • Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005; 201:1479–86.
  • Ruperto N., Lovell D. J., Quartier P., Paz E., Rubio-Perez N., Silva C. A., et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372:383–91.
  • Lovell DJ, Giannini EH, Reif A., et al, for Pediatric Rheumatology Collaboratve Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000; 324: 763-9.
  • Horneff G., De Bock F., Foeldvari I., Girschick H. J., Michels H., Moebius D., et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009; 68:519–25.
  • Lovell D., Ruperto N., Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359(8):810–820
  • Herlins T. Tocilizumab:the evidence for its place in the treatment of juvenile idiopathic arthritis. Core Evidence. 2009; 4:181-189.
  • Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with JIA: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372(9636): 383–391.
  • Biester , Deuter C, Michels H, Haefner R, Kuemmerle J. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007; 91(3): 319–324.
  • Sarah Ringold, Pamela F. Weiss, Timothy Beukelman et al. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening AmongChildren Receiving Biologic Medications. Arthritis&Rheumatism. 2013;65(10):2499–2512.
  • Sbornikklinicheskihprotokolovpoprofiljupediatrija (Collection of clinical protocols on the profile of pediatrics) [in Russian]. 1th ed. 2014. 161-188 p.
  • Otchetnaja forma № 14 «Svedenija o dejatel'nostistacionara», za 2008-2016gody, dannyeotdelastatistiki KF «UMC» NNCMD (Report form No. 14 "Information on the activities of the hospital", for 2008-2016years, data of the statistics department of the CF "UMC" NNCMD) [in Rusiian].
  • Otchetnaja forma № № 30 «Svedenijaobuchrezhdeniizdravoohranenija», za 2008-2016gody, dannyeotdelastatistiki KF «UMC» NNCMD (Report form No. 30 "Information on the establishment of health care", for 2008-2016, data of the Statistics Department of the "UMC" CFMC.) [in Russian].
  • Otchetpo 007 programme «Perspektivnyefeto-infantnyetehnologiisnizhenijareproduktivnyhidetskihpoter'» AO «Nacional'nyj nauchnyjcentrmaterinstvaidetstva» ponapravleniju «Optimizacijadiagnostikiilechenijajuvenil'nyhhronicheskihartritov» 2011- 2013gg. (Report on 007 program "Perspective feto-infant technologies for reducing reproductive and childhood losses" JSC "National Research Center for Maternity and Childhood" in the direction "Optimization of diagnosis and treatment of juvenile chronic arthritis" 2011-2013gg) [in Russian].